Posts

Apnimed secures $192M upsized IPO to launch sleep apnea pill Oxnimbi

on

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Xpovio mulligan in endometrial cancer misses primary endpoint while Karyopharm presses on in myelofibrosis

on

Novo Nordisk Bets on HERMES and ARTEMIS to Salvage Ziltivekimab CKD Program After ZEUS Failure

on

Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote

on

Alnylam Cuts Amvuttra Sales Guidance as Second-Line Demand Normalizes, Hitting Stock

on

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

BMS pushes key Cobenfy and milvexian readouts to 2027 amid strong quarter and raised guidance

on

Friday Five: Freenome's CRC Test Wins FDA Nod

on

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

on

BMS CEO Boerner Says No Compulsion to Chase Deals Despite Quiet M&A Year

on

Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition

on

FTC sues Hims & Hers over data privacy and deceptive billing practices

on

Doctronic acquires Summer Health to expand into pediatric care

on

VoxNeuro Gains FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software

on

Recent Biotech Reverse Mergers Accelerate BTK‑Based Immune & Inflammatory Drug Programs

on

Relation Deepens GSK AI Pact With Up to $110M Deal Aiming at Transformationally Different Success Rates in Drug Discovery

on

Caldera snaps up Synlogic in reverse merger to hit Nasdaq and fund IBD pipeline through 2029

on

AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia

on

Insilico Medicine Receives FDA Fast Track Designation for AI-Driven Pan-TEAD Inhibitor ISM6331 in Advanced Mesothelioma

on

ThinkSono Receives FDA Clearance for Ultrasound AI Software for Blood Clots

on

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

on

Teva's Innovation Engine Offsets Generics Slump, Leaving Analyst Shocked by Ajovy Surge

on

AbbVie Scores First Rinvoq Alopecia Nod in EU

on

Biogen flips 2026 revenue guidance from expected decline to sales increase

on

Atea's hep C pill equal to Gilead's

on

Claris collects $118M to take eye drop into pivotal testing next year

on

Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win

on

MannKind Receives FDA Approval for Furoscix ReadyFlow Autoinjector for Edema in Heart Failure and CKD

on

GSK unveils 3‑year cost‑saving plan to fund late‑stage R&D and move research HQ to Cambridge from AZ”,

on

FDA's re‑evaluation of Capricor and Replimune drugs underscores that review ≠ reversal

on